NUFIRI

NuCana plc · Phase 1 active Small molecule

At a glance

Generic name	NUFIRI
Also known as	Campto, Camptosar, Nucleotide analogue
Sponsor	NuCana plc
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer (PHASE2)
A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NUFIRI CI brief — competitive landscape report
NUFIRI updates RSS · CI watch RSS
NuCana plc portfolio CI